US0231112063

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- August 31, 2025 08:30 ET  | Source: Amarin…

3 months ago

New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…

3 months ago